Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?

Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?

Pelvic Melanoma relapse occurs in 15% of patients with loco regional metastases, and 25% of cases do not respond to new target-therapy and/or immunotherapy. Melphalan hypoxic pelvic perfusion may, therefore, be an option for these non-responsive patients. Overall median survival time (MST), stratifi...

Full description

Bibliographic Details
Main Authors: Stefano Guadagni, Giammaria Fiorentini, Marco Clementi, Giancarlo Palumbo, Paola Palumbo, Alessandro Chiominto, Stefano Baldoni, Francesco Masedu, Marco Valenti, Ambra Di Tommaso, Bianca Fabi, Camillo Aliberti, Donatella Sarti, Veronica Guadagni, Cristina Pellegrini
Format: Article
Language:English
Published: MDPI AG 2017-11-01
Series:International Journal of Molecular Sciences
Subjects:
melanoma
BRAF
Melphalan
pelvic perfusion
hypoxia
stopflow
Online Access:https://www.mdpi.com/1422-0067/18/11/2382

Similar Items

Similar Items